Sun Pharma to get dengue vaccine technology from ICGEB

iggebPharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.

The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.

A serotype is a serologically distinguishable strain of a microorganism.

Currently, half of the global population lives under dengue threat; and an estimated 390 million infections occur worldwide every year with approx. 100 million cases of clinical disease and over 25,000 deaths. All four dengue virus serotypes are now endemic in India.

Currently, there are no available antivirals, which presents a public health challenge in India and other parts of the world, including developed nations. There is no specific treatment other than supportive clinical care, which is extremely difficult in developing countries with poor resources.

“Our new collaboration with ICGEB for developing an affordable dengue vaccine is part of our programme for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world,” said Kirti Ganorkar, Executive VP & Head, Global Business Development, Sun Pharma.

International Centre for Genetic Engineering and Biotechnology (ICGEB) has developed a dengue vaccine based on a tailored recombinant virus-like-particle (VLP). The vaccine contains host-receptor binding domain of envelope protein of all the four dengue virus serotypes.

According to the agreement signed, ICGEB shall disclose and make available to Sun Pharma all such existing ICGEB know-how as well as effective completion of technology transfer by ICGEB to Sun Pharma within stipulated timeframe. Sun Pharma will fund & support further development of the vaccine candidate and existing ICGEB know-how and patents.

ICGEB will grant Sun Pharma exclusive rights and licenses for development and commercialisation of this vaccine globally and it will receive pre-defined royalty & payments.

The Company has past experience in development of Hep-B and Typhoid vaccines, as well as complex vaccines, such as HPV and Malaria.

Dengue is a neglected mosquito-borne viral disease that is rapidly spreading globally. Dengue incidence has increased by more than 30-fold in the past 50 years.

The Sun Pharma – ICGEB dengue vaccine candidate is expected to provide a competitive edge over others in all three critical parameters of Safety, Efficacy & Affordability that define an ideal dengue vaccine.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.

“The immediate priority of this partnership is to complete the Toxicology studies for further development of the program,” Sun Pharma said.

This is the second collaboration between Sun Pharma and ICGEB focusing on dengue.

The first one announced in May 2016 was related to the development of a botanical drug for treatment of Dengue. The current collaboration is focussed on developing a safe & effective vaccine for the prevention of dengue.

Initial findings of ICGEB’s dengue vaccine indicate that the candidate induces serotype specific non-cross-reactive and strongly neutralizing antibodies without disease enhancing concerns.

These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programs that are developed or in development globally.

This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population.

Dr Salunke, Director – International Centre for Genetic Engineering and Biotechnology (ICGEB) said, “Despite recent approval of a dengue vaccine and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious dengue vaccine still faces major challenges. Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations.”

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and one of India’s largest pharmaceutical company.

It provides affordable medicines in over 150 countries across the world.

Sun Pharma’s global presence is supported by 47 manufacturing facilities spread across 6 continents. The consolidated revenues for 12 months ending March 2016 are approximately U$ 4.3 billion.

It has 32 brands and 14 API manufacturing facilities across the globe.

The International Centre for Genetic Engineering and Biotechnology is an international, non-profit research organization.

The ICGEB provides a scientific and educational environment and conducts innovative research in life sciences for the benefit of developing countries. It strengthens the research capability of its Members through training and funding programmes and advisory services and promotes biotechnology internationally.

The Centre is dedicated to advanced research and training in molecular biology and biotechnology and applies the latest techniques in the fields of biomedicine, crop improvement, environmental protection/remediation, biopharmaceuticals and biopesticide production.



Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been terminated.The total investment will be euro 16.875 million, which comes to about...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS primarily develops, manufactures and markets products across various therapeuti...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta tablets of Boehringer Ingelheim Pharmaceuticals, Inc.An Abbreviated New Drug ...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The product is currently marketed in 33 countries, including 21 European Union coun...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, r...
Aditya Birla´s fashion and retail unit ties up with UK luxury brand Ted Baker Aditya Birla Fashion and Retail Ltd said it entered into agreement with UK based fashion brand Ted Baker.Ted Baker London is a British luxury clothing retail company."We are happy to join hands with Ted Baker and build a strong presence for the brand with Indian consumers. This partnership will enable our consumers to explore to a new world of fashio...
Lypsa Gems to sell via Gitanjali Group’s jewelsouk.com Lypsa Gems and Jewellery Ltd said it tied up with Jewelsouk.com to sell ‘Lypsa Atelier’ branded diamond-studded jewellery.“This tie-up is part of our E-commerce push. Lypsa Atelier is currently available on Flipkart, Snapdeal, Craftsvilla, Shopclues in addition to Jewelsouk.”, said Jeeyan Patwa, Director, Lypsa Gems and Jewellery Ltd.Lypsa plans to s...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement setting out the process, timelines and other requisite detail will be released in du...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference l...
India overdependent on China for medicines – study India may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an "overwhelming dependence" on China for the raw material required to produce these drugs, industry association Assocham said.Indian companies depend on China to supply them with the main raw material in drug making -- known as Active Pharmaceuti...
Bajaj Finance to provide auto loans to Baxi drivers Baxi, which operates commercial two wheelers, said it has partnered with Bajaj Finance Limited to finance salaried individuals who want to buy new bikes with the option to operate on a ride share basis.As part of the agreement, Bajaj Finance will provide attractive loans with minimum processing fees, and very low down payment, to salaried individuals who...
US Govt agency to help disburse loans to Indian SMEs RBL Bank and NeoGrowth Credit Pvt will provide loans to small and medium enterprises in the Indian retail segment that are excluded from mainstream funding and financing with the help of a US government agency.The funding will be backed by the Overseas Private Investment Corporation (OPIC) -- a US Government organization that mobilizes private capita...
ABB creates record with 1.2 mln volt transformer for new India grid Power generator ABB said it developed, manufactured and energized a 1.2 mln volts ultra high voltage power transformer to support India’s plans to build a 1,200 kV transmission system.The new grid will supplement the existing 400 kV and 800 kV networks as demand for electricity increases."The 1.2 million volt transformer represents the highest alte...
Lupin licenses taste-masking technology from Monosol for paediatric tablets Pharma Major Lupin Ltd. said its US subsidiary, Lupin Pharmaceutical Inc., has agreed to license technology from Monosol Rx to develop multiple paediatric-focused products.Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology.MonoSol Rx’s PharmFilm technology is a drug delivery platform tha...
Ruchi Soya to plant oil palm in 25,000 hectares in Arunachal Pradesh Agri and Food FMCG company Ruchi Soya Industries Ltd. said it signed an agreement with the Government of Arunachal Pradesh to boost palm oil production through development of quality palm plantations and human capacity building.With this agreement, Ruchi Soya Industries Limited now has obtained permission for oil palm development in 45,000 hectares, cove...